# Successful Re-administration and Extended Dosing of Brentuximab Vedotin Monotherapy for Relapsed Anaplastic Large Cell Lymphoma in a Vulnerable Patient

## TL;DR

This paper describes a successful long-term treatment with Brentuximab Vedotin in a vulnerable patient with relapsed lymphoma.

## Contribution

The study demonstrates extended BV monotherapy re-administration in an elderly, high-risk patient over 4.3 years.

## Key findings

- BV monotherapy was successfully re-administered in a vulnerable patient.
- Extended treatment duration of 4.3 years was achieved without severe neurotoxicity.
- This approach offers new treatment options for elderly or frail patients.

## Abstract

Brentuximab vedotin (BV) monotherapy has significant clinical efficacy against relapsed anaplastic large cell lymphoma. While BV monotherapy re-administration and extended duration of treatment show therapeutic potential, particularly in patients ineligible for autologous hematopoietic stem cell transplantation or conventional salvage chemotherapy due to advanced age or poor performance status, long-term administration is frequently limited by cumulative neurotoxicity. Herein, we present a case of successful BV monotherapy re-administration and extended treatment over 4.3 years in a vulnerable patient. This therapeutic approach expands treatment options available for elderly patients and those with poor performance status.